EGFR and metastatic colorectal cancer: For the treatment of colorectal cancer, antibodies targeting the epidermal growth factor receptor (EGFR) like cetuximab and panitumumab were the first molecularly targeted therapeutics to enter the clinical arena [1–3] and they are approved as first line treatment for RAS wild-type non-resectable metastatic colorectal cancer [4–7].